AU2001226029A1 - Pharmaceutical formulation and method for pulmonary and oral delivery - Google Patents

Pharmaceutical formulation and method for pulmonary and oral delivery

Info

Publication number
AU2001226029A1
AU2001226029A1 AU2001226029A AU2602901A AU2001226029A1 AU 2001226029 A1 AU2001226029 A1 AU 2001226029A1 AU 2001226029 A AU2001226029 A AU 2001226029A AU 2602901 A AU2602901 A AU 2602901A AU 2001226029 A1 AU2001226029 A1 AU 2001226029A1
Authority
AU
Australia
Prior art keywords
pulmonary
pharmaceutical formulation
oral delivery
oral
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001226029A
Other languages
English (en)
Inventor
Robert Schultz
Gary Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dura Pharmaceuticals Inc
Original Assignee
Dura Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dura Pharmaceuticals Inc filed Critical Dura Pharmaceuticals Inc
Publication of AU2001226029A1 publication Critical patent/AU2001226029A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
AU2001226029A 2000-01-10 2000-12-28 Pharmaceutical formulation and method for pulmonary and oral delivery Abandoned AU2001226029A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48054900A 2000-01-10 2000-01-10
US09480549 2000-01-10
PCT/US2000/035427 WO2001051030A1 (fr) 2000-01-10 2000-12-28 Formulation pharmaceutique et procede d'administration pulmonaire et orale

Publications (1)

Publication Number Publication Date
AU2001226029A1 true AU2001226029A1 (en) 2001-07-24

Family

ID=23908389

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001226029A Abandoned AU2001226029A1 (en) 2000-01-10 2000-12-28 Pharmaceutical formulation and method for pulmonary and oral delivery

Country Status (3)

Country Link
US (1) US6616914B2 (fr)
AU (1) AU2001226029A1 (fr)
WO (1) WO2001051030A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
WO2003020241A2 (fr) * 2001-09-05 2003-03-13 Vectura Limited Poudres fonctionnelles administrees par voie orale
GB0128148D0 (en) 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
CN1642524B (zh) * 2002-03-12 2011-05-18 微计量治疗公司 通过吸入部位特异性递送联合施用的药物
EP1503754B1 (fr) * 2002-04-19 2005-11-23 Yissum Research Development Company, of The Hebrew University of Jerusalem Composes beta-agonistes contenant des groupes donneurs d'oxyde nitrique et des groupes piegeurs d'especes oxygenees reactives et leur utilisation dans le traitement de troubles respiratoires
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
US8273331B2 (en) * 2002-08-21 2012-09-25 Norton Healthcare Ltd. Inhalation compositions
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
US20060247216A1 (en) * 2002-10-25 2006-11-02 Haj-Yehia Abdullah I Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
JP2007533387A (ja) 2004-04-21 2007-11-22 イノベータ バイオメド リミテッド 吸入器
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
EP1991532B1 (fr) 2006-02-24 2017-01-11 Rigel Pharmaceuticals, Inc. Compositions et méthodes destinées à l'inhibition de la voie jak
US20080279784A1 (en) * 2007-05-07 2008-11-13 Questcor Pharmaceuticals, Inc. Nasal administration of benzodiazepines
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
WO2009121039A2 (fr) * 2008-03-28 2009-10-01 Hale Biopharma Ventures, Llc Administration de compositions de benzodiazépine
US9352137B2 (en) * 2008-10-29 2016-05-31 Warsaw Orthopedic, Inc. Drug cartridge for delivering a drug depot comprising a bulking agent and/or cover
CA2749217C (fr) 2009-01-23 2017-03-21 Rigel Pharmaceuticals, Inc. Compositions et procedes pour l'inhibition de la voie jak
KR101703695B1 (ko) 2009-05-22 2017-02-08 큐알엔에이, 인크. 전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
TWI589313B (zh) 2010-01-05 2017-07-01 麥可朵斯斯若波特公司 醫藥遞送封裝及吸入器
JP5981850B2 (ja) 2010-01-25 2016-08-31 カッパーアールエヌエー，インコーポレイテッド ＲＮａｓｅＨ１に対する天然アンチセンス転写物の阻害によるＲＮａｓｅＨ１関連疾患の治療
AU2011210352A1 (en) 2010-01-26 2012-08-09 Radikal Therapeutics Inc. Compositions and methods for prevention and treatment of pulmonary hypertension
EP3415139B8 (fr) 2011-06-14 2022-05-18 Neurelis, Inc. Administration de benzodiazépine
AU2013235729B2 (en) 2012-03-23 2017-06-01 Baylor University Compositions and methods for inhibition of cathepsins
WO2016067252A1 (fr) 2014-10-31 2016-05-06 Glaxosmithkline Intellectual Property Development Limited Formulation de poudre
WO2020092845A1 (fr) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Modes de réalisation d'un procédé et d'une composition permettant de traiter la leucémie myéloïde aiguë
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
BR112022001418A2 (pt) 2019-08-08 2022-06-07 Rigel Pharmaceuticals Inc Compostos e método para tratar a síndrome de liberação de citocinas
WO2021030526A1 (fr) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Procédé de blocage ou d'amélioration du syndrome de libération des cytokines
US11116737B1 (en) * 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
TW202346291A (zh) 2022-03-23 2023-12-01 美商雷傑製藥公司 作為ｉｒａｋ抑制劑的嘧啶—２—基—吡唑化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260306A (en) * 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
ATE274955T1 (de) * 1999-05-03 2004-09-15 Battelle Memorial Institute Arzneizusammensetzungen zur aerosolbildung und zu inhalationszwecken

Also Published As

Publication number Publication date
US6616914B2 (en) 2003-09-09
US20010041190A1 (en) 2001-11-15
WO2001051030A1 (fr) 2001-07-19

Similar Documents

Publication Publication Date Title
AU2001226029A1 (en) Pharmaceutical formulation and method for pulmonary and oral delivery
AU2002319653A1 (en) Method for oral drug delivery
AU2001280188A1 (en) Pyrazolopyridine compound and pharmaceutical use thereof
AU3403201A (en) Drug delivery device and method
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
AU2002239397A1 (en) Drug formulation having improved oral tolerability
AU5326100A (en) Pharmaceutical compositions and methods for use
AU2001294920A1 (en) Chrono delivery formulations and method of use thereof
AU2002354476A1 (en) Pyrazolopyridine derivatives and medicinal use thereof
AU2001284444A1 (en) Preparations for oral administration
EG23994A (en) Pharmaceutical compositions for oral and topical administration
AU2001232017A1 (en) Pharmaceutical composition for pulmonary delivery
AU3201701A (en) Pharmaceutical composition for pulmonary delivery
AU1141101A (en) Pharmaceutical aerosol formulations comprising s-salmeterol
AU2001252741A1 (en) Pharmaceutical composition containing itraconazole with gastric ph-independentlyimproved solubility and preparation method thereof
AU2002334123A1 (en) Anaesthetic compositions and method for their administration
AU2570001A (en) Pharmaceutical composition and method for its manufacture
AU2001258714A1 (en) Herbal composition useful for treatment or oral cavity and method for its local delivery thereof
AU4876701A (en) Peptide derivatives and medicinal compositions
AU5483600A (en) Pharmaceutical materials and methods for their preparation and use
AU2001259564A1 (en) Pharmaceutical compositions and methods for use
AU2001262928A1 (en) Pharmaceutical compositions and their use
AU2001274236A1 (en) Dry-powder pharmaceutical formulation for inhalation comprising alpha4-intergrinantagonist
AU2001260083A1 (en) New pharmaceutical composition and the process for its preparation
AU6473699A (en) Aqueous drug formulation for oral application